Drug Profile

BIIB 063

Alternative Names: anti-CD40 - Biogen; BIIB063

Latest Information Update: 26 Dec 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biogen
Class Monoclonal antibodies
Mechanism of Action CD40 ligand inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Sjogren's syndrome

Most Recent Events

03 Nov 2017 Pharmacokinetics, pharmacodynamics and immunogenicity data from a phase I SAD trial in Healthy volunteers presented at the 81^st American College of Rheumatology and the 52^nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
17 Apr 2017 Biogen terminates phase I trial in healthy volunteers in United Kingdom, due to preclinical safety findings in non-human primates (SC, IV) (NCT02555085)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com